783 related articles for article (PubMed ID: 12750693)
1. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
2. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
3. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
5. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
6. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
8. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
9. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
10. Resistance to targeted therapy in chronic myelogenous leukemia.
Hochhaus A; Erben P; Ernst T; Mueller MC
Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
12. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic and molecular mechanisms of resistance to imatinib.
Hochhaus A
Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
[TBL] [Abstract][Full Text] [Related]
14. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Gumireddy K; Baker SJ; Cosenza SC; John P; Kang AD; Robell KA; Reddy MV; Reddy EP
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1992-7. PubMed ID: 15677719
[TBL] [Abstract][Full Text] [Related]
15. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
16. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
17. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Khorashad JS; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo JV; Goldman JM; Apperley JF; Kaeda J
Leukemia; 2006 Apr; 20(4):658-63. PubMed ID: 16467863
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
19. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
Nimmanapalli R; Bhalla K
Oncogene; 2002 Dec; 21(56):8584-90. PubMed ID: 12476305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]